Israel Justus Simon, Marcelin Laura-Maria, Thomas Christian, Szczyrbová Eva, Fuessel Susanne, Puhr Martin, Linxweiler Johannes, Yalala Shivani, Zwart Wilbert T, Baniahmad Aria, van Goubergen Jasper, Itkonen Harri M, Sharp Adam, O'Neill Edward, Pretze Marc, Miederer Matthias, Erb Holger H H
Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, 779 00, Czech Republic.
J Exp Clin Cancer Res. 2024 Jul 17;43(1):194. doi: 10.1186/s13046-024-03125-5.
Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus. Therefore, the Department of Urology Dresden hosted an international meeting for scientists and clinical oncologists to discuss the newest advances in AR research. The 2nd International Androgen Receptor Symposium was held in Dresden, Saxony, Germany, from 26-27.04.2024, organised by Dr. Holger H.H. Erb. Following the format of the first meeting, more than 35 scientists from 8 countries attended the event to discuss recent developments, research challenges, and identification of venues in AR research. An important new feature was the involvement of PhD students and young investigators, acknowledging the high scientific quality of their work. The symposium included three covers: new advances from clinical research, basic and translational research, and novel strategies to target AR. Moreover, based on its increasing clinical relevance, a PSMA theranostic mini-symposium was added at the end of the AR symposium to allow the audience to discuss the newest advances in PSMA theranostic. This report focuses on the highlights and discussions of the meeting.
持续探索雄激素受体(AR)至关重要,因为它在前列腺癌(PCa)等多种疾病中发挥着关键作用,是一个重要的治疗靶点。因此,德累斯顿泌尿外科举办了一次面向科学家和临床肿瘤学家的国际会议,以讨论AR研究的最新进展。第二届国际雄激素受体研讨会于2024年4月26日至27日在德国萨克森州的德累斯顿举行,由霍尔格·H·H·埃尔布博士组织。按照第一次会议的形式,来自8个国家的35多名科学家参加了此次活动,讨论AR研究的最新进展、研究挑战以及确定研究方向。一个重要的新特点是博士生和年轻研究人员的参与,认可了他们工作的高科学质量。研讨会涵盖三个方面:临床研究的新进展、基础与转化研究以及靶向AR的新策略。此外,鉴于其临床相关性日益增加,在AR研讨会结束时增加了一个PSMA诊疗一体化小型研讨会,以便与会者讨论PSMA诊疗一体化的最新进展。本报告重点介绍会议的亮点和讨论内容。